GammaTile NeuroNexus Webinar: Newly Dx Brain Mets Registry Data Results

Neurosurgeon Matthew J. Shepard, MD, discusses key findings from the Prospective Registry study, “Local Control and LMD After Resection and GammaTile Brachytherapy for Newly Diagnosed Brain Metastases: Results from the STaRT Registry," published in the Journal of Neuro-Oncology, which reported high local control and low overall toxicity at 12 months in patients with newly diagnosed brain metastases.(1)

Dr. Shepard is an Assistant Professor of Neurosurgery at the Drexel University School of Medicine and the Director of Brain Tumor Research at Allegheny Health Network Neuroscience Institute.

REFERENCE: 1. Kite T, Hanft S, Zeller S, et al. Local control and leptomeningeal disease after resection and GammaTile brachytherapy for newly diagnosed brain metastases: results from a prospective study. J Neurooncol. 2026;176(3):199. 

**

Quotes are based on the personal experience and learnings of the featured healthcare professionals.

GammaTile® is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). GammaTile should not be used for patients with a known history of hypersensitivity to bovine-derived materials. More information on indications, contraindications, warnings, and instructions for use can be found in the GammaTile Instructions for Use. Learn more at gammatile.com.

CAUTION: The law restricts these devices to sale by or on the order of a physician.

©2026 GT Medical Technologies, Inc. GammaTile® is a registered trademark of GT Medical Technologies, Inc. All rights reserved. MKT-598-01

Видео GammaTile NeuroNexus Webinar: Newly Dx Brain Mets Registry Data Results канала GammaTile | Brain Tumor Treatment